Thursday, June 14, 2007
Advisory Panel 14 - Zimulti 0
An FDA advisory panel of outside experts voted 14-to-0 that based on data provided to date, it was impossible to conclude that rimonabant has a "favorable risk-benefit profile," and recommended that Zimulti not be approved to aid weight loss by obese and overweight individuals.
If this was a baseball game (or even football game), that score adds up to a real bad day for Sanofi-Aventis.
A final decision is expected by July 27 by the FDA.
If this was a baseball game (or even football game), that score adds up to a real bad day for Sanofi-Aventis.
A final decision is expected by July 27 by the FDA.
Subscribe to Posts [Atom]
